Now that earnings season is over, and we prepare for the upcoming ADA Scientific Sessions in that beautiful city by the bay some reflective thoughts on what we have learned and what lies ahead.
Looking at the pharma side of the ledger first it can be best summed up by stating the more things change the more they stay the same. While there was a time when it looked like this was a three-horse race between Lilly – Novo Nordisk and Sanofi – recent results confirmed what we have long known when it comes to diabetes therapies it’s battle . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.